SCHEMBL1242691

SCHEMBL1242691

CC(C)(C)N(C(=O)O)c1ccc(F)c(Br)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.35
TDO2 P48775 2/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC9A1 P19634 2/20 0.32
FAAH O00519 1/20 0.32
AR P10275 1/20 0.31
HTT P42858 2/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL688212 0.85 CES2 (0.38) NPC1RAB9ANPSR1LMNATSHR
SCHEMBL8589226 0.82 ALOX15 (0.40) TSHRCYP2C9ARMEN1ALDH1A1
SCHEMBL2082910 0.82 MEN1 (0.41) NPC1RAB9ALMNATSHRMEN1
SCHEMBL20577786 0.81 KCNQ2 (0.33) ARHTTMEN1ALDH1A1KMT2A
SCHEMBL1259292 0.79 ESR1 (0.43) LMNAARMEN1ALDH1A1HPGD
SCHEMBL29251015 0.79 MTNR1A (0.33) IDO1
SCHEMBL28920195 0.78 SOS1 (0.31)
SCHEMBL21351910 0.78 LTC4S (0.38) NPC1RAB9ALMNATSHRCYP1A2
SCHEMBL17257958 0.77 POLB (0.37) IDO1NPSR1LMNACYP1A2CYP2D6
SCHEMBL26621379 0.77 HDAC1 (0.39) ARALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879878-B2 such as {2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino]ethyl}phosphonic acid, used as platelet aggregation inhibitor and purinergic receptor (P2Y12) inhibitors; therapy for circulatory diseases involving thrombosis via platelet aggregation ASTELLAS PHARMA INC. (JP) 2011-02-01 US disclosed